The HCPLive Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.
September 16th 2024
A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.
September 13th 2024
September 12th 2024
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
fNIRS Investigation of Brain Activity, Cognitive Function and Sleep Quality in Major Depression
April 6th 2023A new study has found individuals with depression and insomnia show significantly less activity in the prefrontal cortex during verbal fluency tests, suggesting that sleep quality is an important indicator in fNIRS screening.
Investigators Identify Risk Factors for Drug-Induced Parkinsonism for Schizophrenia Patients
Various psychiatric symptoms, including more severe negative symptoms, lower cognition status, and lower excited symptoms were significantly linked to drug-induced parkinsonism induction.
FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application
Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.
New Research Seeks Explanation of Antidepressant Placebo Effect
The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.